NCT03985384已完成4 期
Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2019年4月30日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Rate of change in non-calcified plaque volume
研究概览
简要总结
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
详细描述
To determine the effects of semaglutide therapy on the morphology and composition of non-calcified coronary atherosclerotic plaque (NCP), including the progression of plaque volume.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women with type 2 diabetes with a glycated hemoglobin level of 7.0% or more, drug naïve, or treated with oral agents and/or basal insulin. For patients on basal insulin at entry, the PI will consider dose reduction of basal insulin according to A1c and risk for hypoglycemia. Patients on SGLT-2 inhibitors may be screened but the agents must be discontinued at least 30 days prior to randomization.
- •Age > 40 years of age at the time of the initial Screening visit (V1) with a diagnosis of T2DM in accordance with American Diabetes Association (ADA) guidelines and with at least one cardiovascular risk factor (hypertension, high cholesterol, family history of premature heart disease or past/current smoking) or prior ASCVD (prior stroke, TIA, claudication, coronary artery disease)
- •Willingness to participate in the study and ability to sign informed consent
- •In the investigator's opinion subjects are willing and likely able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures whether or not they receive investigational product for the duration of the trial.
排除标准
- •History of type 1 diabetes mellitus or a history of ketoacidosis.
- •Current use of GLP-1-receptor agonists or use of a GLP-1 receptor agonist within 3 mos. of screening.
- •Current Use of SGLT-2 inhibitors within 30 days of screening
- •Subjects on prandial insulin or using an insulin pump or pramlintide.
- •Any clinically significant malabsorption condition.
- •History of one or more severe hypoglycemic episodes within 6 months of Screening (V1) or a severe hypoglycemic episode occurring during the interval between the Screening visit (V1) and randomization.
- •Subjects experiencing a cardiovascular event (e.g., myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening visit (V1) and randomization.
- •Recent ASCVD Event (stroke, heart attack, ACS or revascularization) within 3 months (90 days) of the screening visit (VI).
- •Subjects undergoing any cardiovascular surgery (e.g., valvular surgery) within 3 months (90 days) of the Screening visit (V1).
- •Subjects with any planned coronary revascularization or peripheral intervention procedure or other cardiovascular surgery.
- •Subjects with New York Heart Association (NYHA) Class III or IV heart failure at the Screening visit (V1).
- •Renal insufficiency (calculated creatinine clearance of <50 ml per minute, MDRD equation).
- •AST or ALT >2 X the upper limit of normal (ULN) at the Screening visit (V1), or a total bilirubin >1.5 X the ULN unless the subject has a history of Gilbert's.
- •Weight in excess of 325 pounds
- •Resting hypotension (systolic blood pressure of <90mmHg) or resting hypertension (systolic blood pressure of >170mmHg or diastolic blood pressure of >110 mmHg) or the treating physician is allowed to adjust background blood pressure medication(s) to lower blood pressure values in order for the subject to be re-assessed for enrollment eligibility.
- •Subject has a history of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
- •Note (1) A subject with a history of malignancy >5 years prior to signing informed consent should have no evidence of residual or recurrent disease.
- •Note (2) a subject with any history of melanoma, leukemia, lymphoma, or renal cell carcinoma is excluded.
- •At randomization, subject has developed a new medical condition, suffered a change in status of an established medical condition, developed a laboratory or ECG abnormality, or required a new treatment or medication during the pre-randomization period which meets any previously described trial exclusion criterion or which, in the opinion of the investigator, exposes the subject to risk by enrolling in the trial.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality at the Screening visit (V1) that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
- •Subjects with known allergy to iodinated contrast material
- •Subject is pregnant or breast-feeding, or is expecting to conceive during the trial, including 35 days following the last dose of blinded investigational product.
- •Females of childbearing potential must use adequate contraceptive methods.
- •Participation in other studies involving investigational drug (s) (Phases 1-4) within 30 days before the Screening visit (V1) and/or during trial participation.
- •Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
- •Personal history of non-familial medullary thyroid carcinoma.
- •Known or suspected hypersensitivity to trial products.
研究组 & 干预措施
Semaglutide
Active Comparator
Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
干预措施: Semaglutide 2 MG/1.5 ML Subcutaneous Solution (Drug)
Placebo
Placebo Comparator
Placebo 1.5 ml, pen-injector for SC injection.
干预措施: Placebo (Drug)
结局指标
主要结局
Rate of change in non-calcified plaque volume
时间窗: 12 months
Rate of change in non-calcified plaque volume
次要结局
- Rate of change in total plaque volume(12 months)
研究者
Matthew J. Budoff
Principal Investigator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Effect Of Semaglutide In Coronary Atheroma PlaqueAtheroscleroses, CoronaryNCT05071417Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León120
已完成
3 期
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityOverweightObesityNCT03574597Novo Nordisk A/S17,609
招募中
4 期
The POST-ACS StudyDiabetes MellitusAcute Coronary SyndromeCoronary Artery DiseaseNCT05322200Swansea Bay University Health Board140
已完成
1 期
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 DiabetesDiabetes Mellitus, Type 2NCT04032197Novo Nordisk A/S101
Unknown
不适用
Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes PatientsAtherosclerosisDiabetes Mellitus, Type 2NCT05147896University Medical Centre Ljubljana100